Botanical species · safety record

Ranunculus bulbosus

The EFSA Compendium of Botanicals holds 7 constituent measurements and 2 adverse-effect records for Ranunculus bulbosus. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Ranunculus bulbosus L.

7Constituent measurements

2Safety records

4Cited sources

38Licensed products (Canada)

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 38 licensed products naming Ranunculus bulbosus as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Source material stated

Plante entière
Plantes fleuries fraîches entières
Whole flowering plant(s)
Whole fresh flowering plant
Whole fresh flowering plant(s)
Whole plant
Whole plant(s)

What the records describe

Constituents measured

Plant parts

Preparations

Effect types

Target tissues

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
3,4-dihydroxybenzoic acid	Aerial part of plants	Solvent extraction	≥ 1.33 Milligram/gram	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier
3,4-dihydroxybenzoic acid	Aerial part of plants	Solvent extraction	≤ 1.42 Milligram/gram	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier
4-hydroxybenzoic acid	Aerial part of plants	Solvent extraction	0.14 Milligram/gram	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier
Anemonin	Unspecified	—	—	—	No resolvable identifier
P-coumaric acid	Aerial part of plants	Solvent extraction	≤ 0.2 Milligram/gram	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier
P-coumaric acid	Aerial part of plants	Solvent extraction	≥ 0.19 Milligram/gram	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier
Protoanemonin	Stem / stalk	Solvent extraction	7765.6 Microgram/gram	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

Effect	Target tissue	Plant part	Preparation	Test organism	Test type	Source
Reproductive	Urogenital	Aerial part of plants	—	Horse (as animal)	Case report	No resolvable identifier
Systemic	Digestive	Aerial part of plants	—	Horse (as animal)	Case report	No resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Shahzad Aslam, M., Choudhary, B.A., Uzair, M., Subhan Ijaz, A. The genus Ranunculus: A phytochemical and ethnopharmacological review. International journal of pharmacy and pharmaceutical sciences, 2012, vol. 4, no. SUPPL. 5, p. 15-22.
Vlcek, J., Klejdus, B., Kuban, V. Determination of phenolic substances in plant materials by capillary electrophoresis and liquid chromatography . Chemicke listy, 2002, vol. 96, no. 1, p. 39-44.
Swerczek, Thomas W. Abortions in Thoroughbred mares associated with consumption of bulbosus buttercups (Ranunculus bulbosus L) . Javma-journal of the american veterinary medical association, 2016, vol. 248, no. 6, p. 669-672.
Bonora, A., Dall'Olio, G., Bruni, A. Separation and quantitation of protoanemonin in Ranunculaceae by normal- and reversed-phase HPLC. Planta medica, 1985, vol. (5), p. 364-7.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature